Trials / Completed
CompletedNCT02875184
A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands
Observational Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, prospective, non-interventional, observational single arm study. 100 patients will be recruited in the Netherlands over a one year period. In all cases, the decision to treat the patient with apremilast will be made prior to the decision to enter the subject into this study. Treatment will be according to routine clinical practice and based on recommendations as per the Summary of Product Characteristics (SPC) of apremilast (Otezla®). Each patient will be followed up for a maximum of 24 months.
Detailed description
The objective of this non-interventional study is to describe patient reported outcomes, effectiveness and real-life use of apremilast treatment in patients with psoriatic arthritis (PsA).
Conditions
Timeline
- Start date
- 2017-03-06
- Primary completion
- 2022-06-30
- Completion
- 2022-06-30
- First posted
- 2016-08-23
- Last updated
- 2023-10-10
Locations
21 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT02875184. Inclusion in this directory is not an endorsement.